



# 2014 AMDM Annual Meeting Agenda

Online evaluation at: [amdm.org/amevaluation.html](http://amdm.org/amevaluation.html)

Wednesday

April 9, 2014

11:00 a.m. – 5:45 p.m.

---

11:00 – 11:15 a.m.	<b>Welcome</b> Judi Smith, AMDM President Karin Hughes, AMDM Annual Meeting Co-Chair Donna Link, AMDM Annual Meeting Co-Chair	Room: White Flint Amphitheatre
11:15 – 12:15	<b>Roundtable Discussion with OIR Management Team</b> Alberto Gutierrez, Ph.D., Director, Office of In Vitro Diagnostics and Radiological Health, FDA <i>alberto.gutierrez@fda.hhs.gov</i>	
12:15 – 1:15	<b>Lunch</b>	Brookside
1:15 – 2:00	<b>IVD Industry Overview</b> Jonathan Kahan, Partner, Hogan Lovells <i>Jonathan.kahan@hoganlovells.com</i>	
2:00 – 2:30	<b>Use of Investigational Devices in Therapeutic Trials</b> David Litwack, CDRH, FDA <i>david.litwack@fda.hhs.gov</i>	
2:30 – 2:45	<b>Break</b>	
2:45 – 3:15	<b>Ten Tips for IVD Manufacturers in 2014</b> Jeffrey N. Gibbs, Director, Hyman, Phelps & McNamara <i>jjgibbs@hpm.com</i>	
3:15 – 3:45	<b>Distribution of In Vitro Diagnostic Products Labeled for RUO &amp; IVD Only Use</b> Shyam Kalavar, CDRH, OIR <i>Shyam.kalavar@fda.hhs.gov</i>	
3:45 – 4:00	<b>Break</b>	
4:00 – 4:45	<b>CLSI Guideline EP17 and EP12: Limits of Detection and Performance Near Cutoff for Qualitative Tests</b> Marina V. Kondratovich, Ph.D., Associate Director for Clinical Studies, Personalized Medicine, OIR, CDRH, FDA <i>marina.kondratovich@fda.hhs.gov</i>	
4:45 – 5:15	<b>The De Novo Process: Making It Work</b> Mark Del Vecchio, Sr. Director, Regulatory Affairs, BD Diagnostics <i>Mark_A_Del_Vecchio@bd.com</i>	
5:15 – 5:45	<b>AMDM Annual Business Meeting</b>	

---



# 2014 AMDM Annual Meeting Agenda

Online evaluation at: [amdm.org/amevaluation.html](http://amdm.org/amevaluation.html)

Thursday

April 10, 2014

9:00 a.m. – 3:15 p.m.

---

8:00 – 9:00 a.m.	<b>Complimentary Breakfast Buffet</b>	White Flint Amphitheatre
9:00 – 9:45	<b>The Changing Regulatory &amp; Policy Environment for Diagnostics - What to Expect in 2015 and Beyond</b> Rick Naples, Sr. VP, Regulatory Affairs, Becton-Dickinson <i>Christine_pasquariello@bd.com</i>	
9:45 – 10:30	<b>Companion Diagnostics Update and Co-Development</b> Pamela Bradley, OIR, CDRH, FDA <i>Pamela.bradley@fda.hhs.gov</i> Jennifer Shen, OIR, CDRH, FDA <i>Jennifer.shen@fda.hhs.gov</i>	
10:30 – 10:45	<b>Break</b>	
10:45 – 11:30	<b>The future of FDA regulation of HIT, including mHealth</b> Bradley Merrill Thompson, Member of the Firm, Epstein Becker Green <i>BThompson@EBGLAW.com</i>	
11:30 – 12:00	<b>Meeting the Clinical Utility Needs of Regulators and Payers for IVDs and Companion Diagnostics</b> Judi Smith, VP, In Vitro Diagnostics & Quality, Precision for Medicine <i>Judi.smith@precisionformedicine.com</i>	
12:00 – 1:00	<b>Lunch</b>	Brookside
1:00 – 1:45	<b>Changes to the IVD Regulations in Europe: What, When, Hot Topics and Areas of Uncertainty</b> Sue Spencer, Head of IVD BSI Group, United Kingdom <i>Sue.spencer@bsigroup.com</i>	
1:45 – 2:25	<b>UDI Implementation for IVDs</b> Steve Gitterman, FDA <i>steve.gitterman@fda.hhs.gov</i>	
2:25 - 3:00	<b>IQCP: How We Can Help Our Customers</b> Andy Quintenz, Scientific & Professional Affairs Manager, Bio-Rad Laboratories <i>Andy_quintenz@bio-rad.com</i>	
3:00 - 3:15	<b>Review &amp; Wrap Up</b> Judi Smith, AMDM President Karin Hughes & Donna Link AMDM Annual Meeting Co-Chairs	

---

